Application Area — Infectious Disease Diagnostics
Skip the Screening. Start Building.
Every infectious disease antibody pair is pre-validated on the platform you actually use — LFA, CLIA or ELISA. Go from catalog to assay in days, not months.
Infectious disease antibody pairs are matched sets of capture and detection monoclonal antibodies used in sandwich immunoassays to detect pathogen antigens or host-response biomarkers in patient samples such as whole blood, serum, plasma, nasopharyngeal swabs or stool. They are the critical raw material component in lateral flow assay (LFA) rapid tests, chemiluminescent immunoassays (CLIA), enzyme-linked immunosorbent assays (ELISA) and fluorescence immunoassays (FIA) for diagnosing bacterial infections, viral diseases, sexually transmitted infections (STIs) and tropical diseases.
In IVD assay development, the antibody pair determines assay sensitivity, specificity and cross-reactivity. A poorly matched pair can fail to detect low-level antigen (low sensitivity) or generate false positives from related pathogens (poor specificity). Sekbio pre-validates every pair in a real sandwich immunoassay on its intended platform before catalog release, eliminating the most time-consuming step in infectious disease assay development.
The most commercially significant infectious disease targets in the current IVD market include:
One Validation. Consistent Performance. Every Batch.
Sekbio infectious disease antibodies are manufactured at industrial scale with tight lot-to-lot CV and full ISO 13485-certified traceability. Validate once, produce with confidence.
All products are available as matched antibody pairs (capture + detection), individual clones or colloidal gold conjugates. Click any product for full specifications and assay data.
| Target / Pathogen | Clinical Application | Formats | Key Specs | Details |
|---|---|---|---|---|
| MxA (Myxovirus Resistance Protein A) | Viral vs. bacterial infection differentiation | LFACLIAELISA | Interferon-induced; high specificity for viral etiology | View MxA Antibody Pair |
| Procalcitonin (PCT) | Sepsis diagnosis, antibiotic stewardship | LFACLIAFIA | Detects intact PCT; LoD <0.05 ng/mL | View PCT Antibody Pair |
| C-Reactive Protein (CRP) | Bacterial infection, inflammation staging | LFACLIAELISA | Wide dynamic range; high-sensitivity CRP available | View CRP Antibody Pair |
| Influenza A / B Antigen | Rapid influenza diagnosis at POC | LFAELISA | Separate A/B clone sets; no cross-reactivity | View Influenza Antibody Pair |
| RSV Antigen | Pediatric RSV lower respiratory infection | LFAELISA | Detects RSV A and B strains; nasopharyngeal matrix | View RSV Antibody Pair |
| HIV Ag/Ab (4th Generation) | HIV infection screening, acute phase detection | CLIAELISA | p24 antigen + IgG/IgM antibody combo detection | View HIV Antibody Pair |
| HCV Antigen | HCV acute infection, window-period shortening | CLIAELISA | Core antigen detection; complements HCV antibody tests | View HCV Antibody Pair |
| HPV Antigen | HPV infection detection, cervical cancer screening | LFAELISA | Targets high-risk HPV types; validated in cervical swab matrix | View HPV Antibody Pair |
| H. pylori Antigen | H. pylori stool antigen test (SAT), non-invasive diagnosis | LFAELISA | Stool matrix validated; high sensitivity in fecal samples | View H. pylori Antibody Pair |
| Strep A Antigen | Rapid Group A streptococcal pharyngitis diagnosis | LFAELISA | Throat swab matrix; results in <5 minutes on LFA | View Strep A Antibody Pair |
| Dengue NS1 / IgG / IgM | Dengue fever acute and convalescent phase diagnosis | LFAELISA | NS1 antigen + IgG/IgM antibody triple combo available | View Dengue Antibody Pair |
| Malaria (P. falciparum / P. vivax) | Malaria rapid diagnostic test (RDT) at POC | LFA | HRP2 and pLDH antigens; detects both P. falciparum and P. vivax | View Malaria Antibody Pair |
| Ebola Nucleoprotein (NP) | Ebola virus disease outbreak rapid detection | LFAELISA | Recombinant NP-based; no live virus required for production | View Ebola Antibody Pair |
Sekbio infectious disease antibody pairs are pre-validated and optimized for four IVD assay platforms. Each pair ships with platform-specific recommended working concentrations.
Colloidal gold and latex bead conjugates for rapid, instrument-free POC testing. Suitable for Strep A, Influenza, RSV, Dengue, Malaria, H. pylori, MxA and Ebola NP.
Chemiluminescent immunoassay pairs for automated analyzer platforms. High-sensitivity formats for PCT, CRP, HIV Ag/Ab and HCV core antigen.
Sandwich ELISA-grade pairs for laboratory quantification. Biotin/streptavidin and HRP-conjugated detection antibodies available for all targets.
Time-resolved fluorescence and fluorescent microsphere conjugates for quantitative POC analyzers. Validated for PCT and CRP.
Not sure which format suits your assay? Sekbio's technical team advises on antibody pair selection, conjugation chemistry and assay configuration based on your target LoD, sample matrix and instrument platform. Contact us or explore our antibody development platforms for custom pair screening and development services.
The most common bottleneck in infectious disease IVD development is antibody qualification — testing multiple clone combinations across pathogens, matrices and platforms before finding a pair that meets clinical performance targets. Sekbio eliminates this step with pre-validated, production-grade antibody pairs.
Every infectious disease antibody pair is screened in a real sandwich immunoassay before catalog listing. You receive a pair that works on your target platform from day one, shortening development timelines from months to days.
Infectious disease assays require rigorous cross-reactivity panels. Sekbio tests each pair against closely related pathogens and endogenous interferents. Cross-reactivity data is available in the product datasheet.
Antibodies are produced in CHO or hybridoma bioreactors at batch sizes from 100 mg to gram scale, with full ISO 13485 documentation for CE and FDA regulatory submissions.
Sekbio antibody scientists provide hands-on support for conjugation optimization, nitrocellulose membrane selection, cut-off calibration and matrix interference troubleshooting — included with every order.
Infectious disease antibody pairs are matched sets of capture and detection antibodies used in sandwich immunoassays to detect pathogen antigens or host-response biomarkers in patient samples. They are the core reagent components in lateral flow assay (LFA), CLIA, ELISA and FIA rapid tests for diagnosing bacterial infections, viral diseases, STIs and tropical diseases.
Sekbio supplies antibody pairs for 13 infectious disease targets: MxA, Procalcitonin (PCT), C-Reactive Protein (CRP), Influenza A/B, RSV, HIV Ag/Ab (4th generation), HCV antigen, HPV antigen, H. pylori antigen, Strep A antigen, Dengue (NS1/IgG/IgM), Malaria (P. falciparum/P. vivax) and Ebola nucleoprotein (NP). All pairs are pre-validated on at least one clinical assay platform before catalog release.
MxA (Myxovirus resistance protein A) is specifically induced by type I interferons during viral infections, making it a selective marker for viral etiology. CRP rises in both viral and bacterial infections and is therefore non-specific on its own. Clinical studies show that combining MxA with CRP significantly improves diagnostic accuracy for distinguishing viral from bacterial respiratory illness, reducing unnecessary antibiotic prescriptions. Sekbio's MxA antibody pair is pre-validated for LFA and CLIA formats.
Yes. Every antibody pair in the Sekbio infectious disease portfolio is pre-validated on the platform it is intended for — LFA, CLIA, ELISA or FIA — before being released to customers. Platform-specific data including signal-to-noise ratios, working concentration ranges, cross-reactivity panels and lot-to-lot CV values are available alongside the product datasheet.
Yes. Sekbio supplies antibody pairs for Ebola nucleoprotein (NP) and HIV antigens raised against recombinant or inactivated antigens — no live virus is used in production. These antibodies are supplied as purified proteins safe for standard laboratory handling and are fully validated for LFA and ELISA diagnostic formats.
The standard MOQ is 1 mg per antibody clone, sufficient for initial assay feasibility studies. For scale-up and routine production, quantities from 10 mg to gram scale are available with full ISO 13485-certified batch documentation and Certificate of Analysis.
Each batch undergoes SEC-HPLC purity testing, SDS-PAGE, binding activity ELISA and platform-specific functional assays. Lot-to-lot CV for key performance parameters is maintained below 10%. All manufacturing is conducted under an ISO 13485-certified quality management system, and full traceability documentation is provided with every shipment for CE and regulatory submissions.
Yes. Sekbio offers end-to-end custom antibody development for novel or emerging pathogen targets not in the catalog — from antigen design and immunization through hybridoma screening, pairing validation and stable cell line establishment. Delivery for a complete custom project is typically 8–12 weeks. Explore our antibody development platforms or contact our team to discuss your target and timeline.
Request a sample, download datasheets, or speak with a Sekbio antibody scientist about your assay requirements.